An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent Xiamen Innovax Biotech (Primary)
- Indications Cervical cancer; Condylomata acuminata
- Focus Pharmacodynamics
Most Recent Events
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Jul 2020 Planned End Date changed from 30 Jul 2020 to 30 Dec 2020.
- 20 Dec 2019 Status changed from not yet recruiting to active, no longer recruiting.